 involved in bile duct injury, specifically B cell antigen presentation versus immunoglobulin production. Specific Aim 2: Determine the contribution of B cells to progression of bile duct injury in murine BA through administration of B cell-depleting agents. This aim has direct translational implications to potential new therapies for human BA. Specific Aim 3: Define
involved in bile duct injury, specifically B cell antigen display versus immunoglobulin product. Specific Aim 2: Determine the contribution of B cell to progress of bile duct injury in murine BA through administration of B cellular telephone - depleting agents. This aim have direct translational implications to likely new therapies for human BA. Specific Aim 3: specify
 ingolved in bile duct injuvy, specifically Y cell entigen presentxtion versus immunoglobulin 'rodyctiob. Specific Aim 2: Determkne the clntributuon id B cells vk progrcfsioh of yioe duct injury in murine BA through adkividtration of B cell-depleting agents. Ehis aik jas direct tragslauiogal jmplications to potential new therzpies fmr human BA. Slecific Aim 3: Define
involved in bile duct injury, specifically B presentation immunoglobulin production. Aim 2: Determine to of bile duct in murine BA administration of B cell-depleting agents. This has direct translational implications to potential new therapies for human BA. Specific Aim Define
 involved in bile duct injury, sPecificallY B celL anTigEn PresEntaTion versus immuNOgloBulin production. SpecifiC Aim 2: DEtERminE ThE contRibutioN Of b CEllS tO pRogReSSiOn of bIle Duct injUry in murinE BA ThRough adminisTRaTion of B celL-dePleting agentS. ThIs aim hAs DirECt traNslAtionAl implICationS to potentIaL New theRApies foR HUmAn BA. specific Aim 3: Define
 involved in bile duct inj ury, speci fical lyB c el l an tige n presentation vers us immunoglobulin prod uctio n. Spec i fi c Aim  2: Det e rm i n e t he  c ont ri b ut ion o f B  cellsto progres sio nof bile duct in jury in mu rin e BA through  ad minist ra tio n  of B  ce ll-de pletin g  agent s. This a im has di r ect tra n s la tion al implications t o  p o tential new th erapie sf or h uma n B A. Specifi cAim 3 :  Define 
 involved_in bile_duct injury, specifically B_cell antigen_presentation_versus immunoglobulin_production._Specific Aim 2:_Determine the contribution_of B cells to_progression of bile_duct_injury in murine BA through administration of B cell-depleting agents. This aim has direct_translational_implications to_potential_new_therapies for human BA. Specific_Aim 3: Define